More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation ...

Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in ...

Nonlinear association seen for effective castration period with metastasis-free survival for any ADT duration.

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. A supplemental new drug application has ...

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy ...

Investigators studied cardiotoxicities of first-line regimens for metastatic hormone-sensitive and nonmetastatic castration-resistant prostate cancer.

Hot flushes in men are sudden, intense heat waves caused by hormone therapy. Learn how to manage them effectively.

Discover new insights into testosterone recovery following androgen deprivation therapy in men undergoing radiotherapy for ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...